Man Group plc Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Man Group plc lessened its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 92.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 55,441 shares of the biopharmaceutical company's stock after selling 680,887 shares during the quarter. Man Group plc's holdings in Amicus Therapeutics were worth $522,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Nuveen Asset Management LLC boosted its holdings in Amicus Therapeutics by 4.4% in the fourth quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company's stock valued at $35,866,000 after acquiring an additional 159,139 shares during the last quarter. Orbimed Advisors LLC lifted its position in shares of Amicus Therapeutics by 300.7% during the fourth quarter. Orbimed Advisors LLC now owns 2,285,400 shares of the biopharmaceutical company's stock worth $21,528,000 after acquiring an additional 1,715,100 shares in the last quarter. Millennium Management LLC grew its position in shares of Amicus Therapeutics by 10.8% during the 4th quarter. Millennium Management LLC now owns 457,014 shares of the biopharmaceutical company's stock valued at $4,305,000 after purchasing an additional 44,449 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Amicus Therapeutics by 10.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 258,149 shares of the biopharmaceutical company's stock worth $2,432,000 after acquiring an additional 24,316 shares in the last quarter. Finally, Hudson Bay Capital Management LP raised its position in Amicus Therapeutics by 26.7% in the 4th quarter. Hudson Bay Capital Management LP now owns 1,804,800 shares of the biopharmaceutical company's stock worth $17,001,000 after purchasing an additional 379,800 shares during the period.

Amicus Therapeutics Price Performance

FOLD traded down $0.08 on Friday, reaching $6.14. 363,099 shares of the company's stock were exchanged, compared to its average volume of 2,873,092. Amicus Therapeutics, Inc. has a twelve month low of $5.81 and a twelve month high of $12.65. The stock has a market cap of $1.89 billion, a PE ratio of -34.03, a P/E/G ratio of 1.51 and a beta of 0.64. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The stock's fifty day moving average price is $6.89 and its 200-day moving average price is $8.61.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company decreased their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, February 20th. Wall Street Zen downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, May 5th. The Goldman Sachs Group cut their price objective on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a report on Friday, May 2nd. UBS Group increased their price target on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Finally, Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $16.22.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.